Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib plus defactinib in recurrent gynecological cancers
NCT05512208Phase 2Recruiting
- Sponsor
- University of Oklahoma
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib, defactinib in endometrioid carcinoma, mucinous ovarian carcinoma (MOC), high grade serous ovarian carcinoma (HGSC), Cervical Cancer (CC), solid tumor, sponsored by University of Oklahoma. Started Feb 2023; status: recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
endometrioid carcinomamucinous ovarian carcinoma (MOC)high grade serous ovarian carcinoma (HGSC)Cervical Cancer (CC)solid tumor
Beyond the preview
Go deeper on NCT05512208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512208.